No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 114 | 134 | 199 | 170 | 183 | 224 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | -61 | -168 | -91 | -155 | -146 | -145 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oxford Nanopore Technologies plc (ONT.L)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Oxford Nanopore Technologies plc, founded in 2005 and originally known as Oxford NanoLabs Limited before its name change in May 2008, is a United Kingdom-based enterprise that specializes in developing and commercializing an innovative system for analyzing diverse molecular structures through nanopore-based sensing. Its product range features a variety of devices, including the portable MinION for sequencing deoxyribonucleic acid and ribonucleic acid, and the MinION Mk1C, which integrates basecalling, data analysis, touchscreen controls, and wireless connectivity. For benchtop operations, the company offers the GridION, capable of running and analyzing up to five MinION or Flongle flow cells, as well as the GridION Mk1 nanopore sequencer. High-yield sequencing is made accessible with the PromethION 2 Solo and PromethION 2, while the PromethION 24 and PromethION 48 provide benchtop nanopore sequencers for multiple users to achieve multi-sample and multi-experiment results. Further complementing these devices are Flongle, an adapter for MinION or GridION units, and VolTRAX, a USB-powered tool designed to automate laboratory processes preceding nanopore sequencing. The company also provides a suite of software solutions: MinKNOW facilitates data acquisition, real-time analysis and feedback, local basecalling, and data streaming; specialized Basecalling tools pinpoint the identity and sequence of bases on DNA/RNA molecules; EPI2ME is a cloud-based platform for comprehensive, real-time analysis of nanopore data; and EPI2ME Labs offers bioinformatics support to help users refine their skills and confidence in analyzing their sequencing data. Additionally, Oxford Nanopore Technologies is actively developing new products such as MinION Mk1D, Ubi, Plongle, and SmidgION. All of its products are available for purchase online.